Prostate Risk Index (PRIX) as a New Method of Risk Classification for Clinically Localized Prostate Cancer

Yoshioka, Yasuo; Inoue, Takehiro

doi:10.1007/s00066-007-1692-3

Cited by 14 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, these models are validated internally or externally. In this regard, the PRIX score is a unique risk prediction model because the PRIX score was not developed on the basis of the statistical analysis of a specific cohort but was developed solely on the basis of correspondence to the other prediction models (6). Therefore, internal validation of the PRIX score cannot be performed, and external validation is required; so far, however, the PRIX score has not been externally validated.…”

Section: Discussionmentioning

confidence: 99%

“…The PRIX score, which ranges from 0 to 6, was previously reported as a scoring system for risk classification of clinically localized prostate cancer (6,7). In this scoring system, a score of 0 points is assigned to a PSA level at diagnosis of ,10.0 ng/ml, 1 point to a PSA of 10.0 -20.0 ng/ml and 2 points to a PSA of 20.0 ng/ml.…”

Section: Definiton Of the Prix Scorementioning

confidence: 99%

“…The Prostate Cancer Risk Index (PRIX) was developed by Yoshioka et al (6,7) and is a simple scoring system for risk stratification of clinically localized prostate cancer that relies on three variables: PSA level at diagnosis, Gleason score at biopsy and clinical T stage. The PRIX score categorizes each variable, and each is assigned a score of 0 -2.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer

Yoshida

Nakayama

Matsuzaki

et al. 2011

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: The Prostate Cancer Risk Index (PRIX) is a simple scoring system for risk stratification of clinically localized prostate cancer that relies on three variables: prostate-specific antigen level at diagnosis, Gleason score at biopsy and clinical T stage. The aim of this study was validation of the ability of the PRIX score to predict biochemical relapse after radical prostatectomy in a series of patients from a single Japanese center. Methods: From 1995 to 2008, 519 patients who underwent radical prostatectomy for clinically localized prostate cancer with no adjuvant therapies were included in the validation cohort. The biochemical relapse-free rate was estimated using the Kaplan -Meier method. The performance of the PRIX score was assessed with Cox proportional hazards regression model, concordance index and a calibration plot. For comparison, the performance of the D'Amico classification was also assessed. Results: Biochemical relapse-free rate continuously decreased as the PRIX score increased. Each 1-point increment in the PRIX score led to an increase in hazard ratio for biochemical relapse. The concordance index of the PRIX score and the D'Amico classification to predict biochemical relapse was 0.719 and 0.730, respectively. The Kaplan -Meier plots and the calibration plots demonstrated the possibility that the PRIX score could present more detailed stratification than the D'Amico classification. Conclusions:The results of our investigation showed that in Japanese patients treated at a single center, the PRIX score can accurately predict biochemical relapse after radical prostatectomy and demonstrates reasonable calibration. The PRIX score may be one option as a prediction model for biochemical relapse after radical prostatectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Definiton Of the Prix Scorementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer

Yoshida

Nakayama

Matsuzaki

et al. 2011

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…38,39 The literature primarily consists of variations of the existing risk stratification groups, but also includes score-based and nomogram-based systems. 38,[40][41][42] Two pretreatment risk stratification models were evaluated in conjunction with the HTA report. 4 Cowen and colleagues created a risk nomogram to predict overall survival at 5, 10 and 15 years and median survival.…”

Section: Alternative Risk Stratification Systemsmentioning

confidence: 99%

Pre-treatment risk stratification of prostate cancer patients:A critical review

Rodrigues

Warde

Pickles

et al. 2012

CUAJ

View full text Add to dashboard Cite

Introduction: The use of accepted prostate cancer risk stratification groups based on prostate-specific antigen, T stage and Gleason score assists in therapeutic treatment decision-making, clinical trial design and outcome reporting. The utility of integrating novel prognostic factors into an updated risk stratification schema is an area of current debate. The purpose of this work is to critically review the available literature on novel pre-treatment prognostic factors and alternative prostate cancer risk stratification schema to assess the feasibility and need for changes to existing risk stratification systems. Methods: A systematic literature search was conducted to identify original research publications and review articles on prognostic factors and risk stratification in prostate cancer. Search terms included risk stratification, risk assessment, prostate cancer or neoplasms, and prognostic factors. Abstracted information was assessed to draw conclusions regarding the potential utility of changes to existing risk stratification schema. Results: The critical review identified three specific clinically relevant potential changes to the most commonly used three-group risk stratification system: (1) the creation of a very-low risk category; (2) the splitting of intermediate-risk into a low-and highintermediate risk groups; and (3) the clarification of the interface between intermediate-and high-risk disease. Novel pathological factors regarding high-grade cancer, subtypes of Gleason score 7 and percentage biopsy cores positive were also identified as potentially important risk-stratification factors. Conclusions: Multiple studies of prognostic factors have been performed to create currently utilized prostate cancer risk stratification systems. We propose potential changes to existing systems.

show abstract

“…PSA is a well-established predictor not only for screening and prognosis [25], but also for follow-up [6,22] after therapy to detect disease recurrence [16] in patients with prostate cancer. The biochemical control definition after surgery is straightforward since the PSA-producing organ is removed.…”

Section: Introductionmentioning

confidence: 99%

PSA after Incidental Irradiation of the Nonmalignant Prostate: Long-Term Changes

et al. 2008

View full text Add to dashboard Cite

show abstract

Prostate Risk Index (PRIX) as a New Method of Risk Classification for Clinically Localized Prostate Cancer

Abstract: PRIX fully corresponded to the Partin Table in terms of pLN+, and corresponded to the other nomograms better than any existing risk-grouping method. PRIX may thus function as a prognostic factor or contribute to patient selection in clinically localized prostate cancer.

Cited by 14 publications

References 19 publications

Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer

Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer

Pre-treatment risk stratification of prostate cancer patients:A critical review

PSA after Incidental Irradiation of the Nonmalignant Prostate: Long-Term Changes

Contact Info

Product

Resources

About